Welcome to our dedicated page for Alterity Therapeutics SEC filings (Ticker: ATHE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alterity Therapeutics Limited filings document a foreign private issuer and development-stage biotechnology company reporting through Form 6-K and incorporated reports tied to Form S-8 and Form F-3 registration statements. The filings record ATH434 and MSA development updates, bioMUSE biomarker publications, FDA meeting communications, medical conference presentations, and Appendix 4C quarterly cash flow and activity reports.
Other disclosures cover shareholder meeting and proxy materials, substantial holding notices, share consolidation or split notices, board and governance changes, and capital-structure matters for securities traded as ASX: ATH and NASDAQ: ATHE.
Alterity Therapeutics Limited has called an online general meeting on 29 May 2026 to vote on several governance and capital-structure changes. Shareholders will consider electing directors Julian Babarczy and Ann Cunningham, a 50:1 consolidation of shares and options, and adjustments to the company’s ADR ratio. The meeting will also vote on issuing up to 100,000,000 options (pre-consolidation) to Mr Babarczy and up to 50,000,000 options to Montoya Pty Ltd ATF Buttercup Trust, an entity associated with director Lawrence Gozlan. In addition, shareholders are asked to lift the employee incentive issue cap to 10% of issued capital and approve issuing up to 1,087,541,633 securities (pre-consolidation) under the Employee Incentive Securities Plan.
Alterity Therapeutics Limited reports that the U.S. FDA has provided positive regulatory feedback in a second Type C Meeting on its planned Phase 3 program for ATH434 in Multiple System Atrophy (MSA). The agency and company reached alignment on key chemistry, manufacturing, and control (CMC) elements, supporting readiness for Phase 3 initiation while manufacturing scale-up progresses in parallel. An End-of-Phase 2 meeting with the FDA remains on track for mid-2026, positioning ATH434 for a pivotal trial in this rare, rapidly progressive neurodegenerative disease with no approved disease-modifying treatments.
Alterity Therapeutics reported new analyses from its Phase 2 trial of ATH434 in Multiple System Atrophy, showing signals of clinical efficacy. Using the new MuSyCA composite scale, placebo patients worsened by about 9.7 points over 52 weeks, while ATH434 slowed progression by 1.9 to 4.0 points, with a 41% relative treatment effect at the 50 mg dose. A separate analysis using modified UMSARS Part I found ATH434 reduced decline versus placebo by 3.1 points at 75 mg and 4.7 points at 50 mg, with relative treatment effects of 35% and 53% and a statistically significant p-value at the lower dose. The company says these findings support ATH434’s disease-modifying potential and its plans to advance into a Phase 3 pivotal trial in MSA.
Alterity Therapeutics Limited, a development-stage enterprise based in Melbourne, submitted a Form 6-K as a foreign private issuer. The filing is incorporated by reference into several existing Form S-8 and Form F-3 registration statements.
Through an attached Appendix 3X, Alterity reports the appointment of Ann Cunningham as a director effective 17 April 2026. The notice states that she currently has no relevant interests in Alterity securities as a registered holder.
Alterity Therapeutics Limited has appointed Ms Ann Cunningham as an independent Non-Executive Director to its Board, effective 17 April 2026. She brings more than 25 years of global pharmaceutical and biotechnology experience, with deep expertise in commercial strategy across neurodegenerative disease and psychiatry.
Cunningham has held senior roles at Eli Lilly and Teva Pharmaceuticals, leading marketing and sales teams and overseeing neurodegenerative and psychiatry portfolios. Her appointment comes as Alterity prepares to advance its lead asset ATH434 into Phase 3 development for Multiple System Atrophy and move toward potential commercialisation.
Alterity Therapeutics Limited filed a Form 6-K highlighting a scientific milestone for its lead drug candidate ATH434. Daniel Claassen, M.D., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will present late-breaking clinical data at the American Academy of Neurology Annual Meeting in Chicago.
The oral presentation, titled “ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale,” is scheduled for Tuesday, April 21, 2026 at 6:21 PM. ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy and additional positive data in an open-label Phase 2 trial in advanced disease.
Alterity is a clinical stage biotechnology company focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders, and is preparing to initiate a Phase 3 pivotal trial in MSA. The company also maintains a broader discovery platform targeting underlying pathology in neurodegenerative diseases.
Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company. He reports direct ownership of 11,688,312 ordinary shares and indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees (Australia) Limited. He also holds several option grants over ordinary shares with exercise prices ranging from $0.0030 to $0.0280 and expirations between August 2026 and August 2030, indicating a sizable long-term equity position.